PXMD Insider Trading

Insider Ownership Percentage: 1.00%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $212.28

PaxMedica Insider Trading History Chart

This chart shows the insider buying and selling history at PaxMedica by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$200k-$100k$0$100k$200kTotal Insider BuyingTotal Insider Selling

PaxMedica Share Price & Price History

Current Price: $0.03
Price Change: +0.30 (1.20%)
As of 01/17/2025 01:00 AM ET

This chart shows the closing price history over time for PXMD up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
FebMarAprMayJunJulAugSepOctNovDecJan$0.03Closing price on 01/19/25:

SEC Filings (Institutional Ownership Changes) for PaxMedica (NASDAQ:PXMD)

4.90% of PaxMedica stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

PaxMedica logo
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.
Read More on PaxMedica

Today's Range

Now: $0.03
Low: $0.03
High: $0.03

50 Day Range

MA: $0.07
Low: $0.03
High: $0.11

52 Week Range

Now: $0.03
Low: $0.03
High: $1.19

Volume

19 shs

Average Volume

49,983 shs

Market Capitalization

$350,610.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of PaxMedica?

PaxMedica's top insider shareholders include:
  1. Howard J Weisman (CEO)
  2. Michael Derby (Major Shareholder)
  3. Michael Derby (Chairman)
  4. Zachary Rome (COO)
  5. Zachary Rome (Director)
  6. John F Coelho (Director)
  7. Karen Larochelle (Director)
Learn More about top insider investors at PaxMedica.